文献速递其他结缔组织病

系统性硬化症患者的SARS-CoV-2疫苗接种:疾病亚型与治疗的影响

SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

这项4期前瞻性研究在51例系统性硬化症(SSc)患者与153例对照中比较两剂灭活SARS-CoV-2疫苗(CoronaVac)的安全性和免疫原性,发现SSc患者完成全程接种后抗SARS-CoV-2-IgG阳性率(64.1% vs 94.2%)和中和抗体阳性率(53.8% vs 76.9%)均低于对照,而霉酚酸酯(MMF)单药治疗与较低的血清转化率(31.3% vs 90%)和中和抗体阳性率(18.8% vs 85%)相关。

要点

  • SSc患者完成两剂CoronaVac后抗体应答中等但低于对照。
  • MMF单药治疗者血清转化率和中和抗体阳性率显著低于其他治疗。
  • 未观察到中重度副作用,疾病亚型不影响疫苗抗体应答。

核心结论

  • CoronaVac在SSc患者中安全性良好,抗体应答中等。
  • 疫苗抗体应答不受疾病亚型影响,但受MMF使用显著影响,提示该亚组患者需额外策略上调疫苗应答。

研究设计与样本

  • 这是一项4期前瞻性研究,纳入51例SSc患者与153例对照,接种两剂灭活SARS-CoV-2疫苗(CoronaVac)。
  • 在每次接种时(D0/D28)及第二剂后6周(D69)检测抗SARS-CoV-2-IgG和中和抗体(NAb),仅纳入基线IgG/NAb阴性且随访期间未感染COVID-19者。
  • 疫苗安全性在所有参与者中评估。

主要发现

  • 患者与对照的中位年龄相当[48(38.5-57)岁 vs 48(38-57)岁,P=0.945]。
  • 患者以弥漫型SSc为主(68.6%),多数(74.5%)合并间质性肺病。
  • 多数患者接受免疫抑制治疗(72.5%),主要为MMF(52.9%)。
  • 完成全程接种后(D69),抗SARS-CoV-2-IgG阳性率(64.1% vs 94.2%,P<0.001)和NAb阳性率(53.8% vs 76.9%,P=0.006)中等,但低于对照。
  • 第一剂应答(D28)较低,两组血清转化率(P=0.958)和NAb阳性率(P=0.537)相当。

关键数值与推荐

  • MMF单药治疗与其他治疗(无治疗/其他DMARDs)相比,血清转化率较低(31.3% vs 90%,P<0.001),NAb阳性率较低(18.8% vs 85%,P<0.001)。
  • 多因素回归分析证实MMF使用而非疾病亚型与血清转化不足相关[OR=0.056(95%CI:0.009,0.034),P=0.002]及NAb阳性不足相关[OR=0.047(95%CI:0.007,0.036),P=0.002]。
  • 未观察到中重度副作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyse the safety, immunogenicity and factors affecting antibody response to Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) vaccination in patients with SSc. METHODS: This is a phase 4 prospective study within a larger trial of two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in 51 SSc patients compared with 153 controls. Anti-SARS-CoV-2-IgG and neutralizing antibodies (NAb) were assessed at each vaccine shot (D0/D28) and 6 weeks after the second dose(D69), only in individuals with negative baseline IgG/NAb and those who did not have coronavirus-19(COVID19) during follow-up. Vaccine safety was also assessed in all participants. RESULTS: Patients and controls had comparable median ages [48(38.5-57) vs 48(38-57) years, P =0.945]. Patients had mostly diffuse SSc (68.6%) and the majority (74.5%) had interstitial lung disease. Most patients were under immunosuppressive therapy (72.5%), mainly MMF (52.9%). After full vaccination (D69), anti-SARS-CoV-2-IgG frequency (64.1% vs 94.2%, P < 0.001) and NAb positivity (53.8% vs 76.9%; P =0.006) were moderate, although lower than controls. The first dose response (D28) was low and comparable for both seroconvertion rates (SC) (P =0.958) and NAb positivity (P =0.537). SSc patients under MMF monotherapy vs other (no therapy/other DMARDs) had lower immunogenicity (SC: 31.3% vs 90%, P < 0.001) and NAb(18.8% vs 85%, P < 0.001). Multiple regression analysis confirmed that MMF use, but not disease subtype, is associated with insufficient seroconversion [odds ratio (OR)=0.056(95% CI: 0.009, 0.034), P =0.002] and NAb positivity [OR = 0.047(95% CI: 0.007, 0.036), P =0.002]. No moderate/severe side-effects were observed. CONCLUSION: CoronaVac has an excellent safety profile and moderate response to anti-SARS-CoV-2 vaccine in SSc. Vaccine antibody response is not influenced by disease subtype and is greatly affected by MMF, reinforcing the need for additional strategies to up-modulate vaccine response in this subgroup of patients. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT04754698.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, et al. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology (Oxford). 2022. PMID: 34894235. doi:10.1093/rheumatology/keab886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。